Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly competitive market.

What Are Second Generation Psychedelics?

Although the health benefits of psychedelics such as psilocybin, MDMA and LSD are widely recognized (and more with each passing day), there are also plenty of reasons to be cautious of their repeated use. The long-term effects of some psychedelics may not be totally clear and their regular use could have some unknown consequences, especially for those that agonize serotonin 5-HT2B receptors, which have been linked to heart valve disease.

In the case of longer-acting psychedelics like psilocybin, time can also be a problem, since therapy can take up to 8 hours a day and become an exhausting process to both patient and provider. Moreover, not all patients are crazy about the “trip” and its hallucinogenic effects, but could still benefit from the anti-depressive and anti-anxiety effects of the drugs.

Psychedelics 2.0 enter the picture to solve those problems: artificially developed molecules with the same benefits as traditional psychedelics, but without the drawbacks. Of course, there is also a financial incentive to these substances—since current psychedelic drugs cannot be patented, proprietary compounds mean a more than interesting investment opportunity.

That is why the biggest names in the industry are bringing new drugs into the game. In no particular order, meet 5 of those companies:

Cybin

Cybin (NYSE: CYBN) is widely known for being ...

Full story available on Benzinga.com

Read More